Pulmonary

New screening tool accurately identifies patients at high risk for idiopathic pulmonary fibrosis

New screening tool accurately identifies patients at high risk for idiopathic pulmonary fibrosis

A new screening tool for electronic medical records accurately identifies patients who are at high risk of having or developing progressive scarring of the lungs, a condition called idiopathic pulmonary fibrosis, according to researchers from Weill Cornell Medicine, NewYork-Presbyterian , the University of Chicago, Brigham and Women’s Hospital and Mayo Clinic. Idiopathic pulmonary fibrosis (IPF) …

New screening tool accurately identifies patients at high risk for idiopathic pulmonary fibrosis Read More »

-Axial-(A)-and-coronal-(B)-images-on-CT-angiography-demonstrating-a-filling-defect-in-the-right-lower-lobe-pulmonary-vein,-consistent-with-pulmonary-vein-thrombosis.-

Pulmonary venous thrombosis in the context of a COVID-19 infection: about a case

The novel coronavirus SARS-CoV-2 (COVID-19) has progressed rapidly to pandemic levels, killing an estimated one million Americans as of May 8, 2022 [1]. Its presentation ranges from asymptomatic to acute respiratory distress syndrome (ARDS) and death. A striking feature of COVID-19 is that it affects all organ systems, presenting with various symptoms and complications unrelated …

Pulmonary venous thrombosis in the context of a COVID-19 infection: about a case Read More »

New Catheter Leads to Remarkable Reduction in Pulmonary Artery Blockage

New Catheter Leads to Remarkable Reduction in Pulmonary Artery Blockage

A device known as BASHIR™ The endovascular catheter (THROMBOLEX, Inc.) significantly reduces the size of blood clots lodged in the pulmonary arteries, leading to improved heart function in patients with pulmonary embolism, researchers from the Lewis Katz School of Medicine have announced. Medicine from Temple University in a Late-Breaking Innovation Session at the 2022 Transcatheter …

New Catheter Leads to Remarkable Reduction in Pulmonary Artery Blockage Read More »

Pulmonary artery denervation takes another step in hypertension

Pulmonary artery denervation takes another step in hypertension

Pulmonary Artery Denervation (PADN) Combined with a Phosphodiesterase-5 Inhibitor Improved Exercise Capacity, Cardiac Function, and Some Clinical Outcomes in Patients With Pulmonary Arterial Hypertension (PAH) in a Controlled Trial fictitious. The primary endpoint of change from baseline in 6-minute walking distance increased in both groups at 30 days, with a median change at 6 months …

Pulmonary artery denervation takes another step in hypertension Read More »